Megs Pharmaceutical Limited

Megs Pharmaceutical Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 46.43% increase. The company also saw a substantial improvement in profitability, with a 51.14% increase in profit. The company's net worth moved up by a moderate rise of 9.51%.

Unlock access to Megs Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Gain comprehensive insights into the Deals and Valuation data of Megs Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Megs Pharmaceutical's trajectory.

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.